EMA accepts to review Pfizer’s MAA for XELJANZ to treat moderate to severe rheumatoid arthritis
The EMA will now initiate its review of the XELJANZ MAA. This application provides additional information to the original MAA submission, including data from the Phase 3 ORAL
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.